Page last updated: 2024-09-03

mk 0663 and Myocardial Infarction

mk 0663 has been researched along with Myocardial Infarction in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arfè, A; Castellsague, J; Garbe, E; Herings, R; Kollhorst, B; Lucchi, S; Masclee, GMC; Perez-Gutthann, S; Romio, S; Schade, R; Schink, T; Schuemie, MJ; Scotti, L; Straatman, H; Sturkenboom, MCJM; Valkhoff, VE; Varas-Lorenzo, C; Villa, M	1
Lesaffre, E	1
Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT	1
Jick, H; Jick, SS; Kaye, JA	1
Ashcroft, DM; Chen, LC	1

Reviews

1 review(s) available for mk 0663 and Myocardial Infarction

Article	Year
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2007

Article

Year

Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7

Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones

2007

Other Studies

4 other study(ies) available for mk 0663 and Myocardial Infarction

Article	Year
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PloS one, 2018, Volume: 13, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; Etoricoxib; Female; Humans; Indomethacin; Ketorolac; Lactones; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Factors; Sulfones	2018
Superiority, equivalence, and non-inferiority trials. Bulletin of the NYU hospital for joint diseases, 2008, Volume: 66, Issue:2 Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Statistics as Topic; Sulfonamides; Sulfones; Thrombolytic Therapy; Treatment Outcome	2008
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal of rheumatology, 2011, Volume: 38, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diclofenac; Etoricoxib; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Osteoarthritis; Peptide Fragments; Prospective Studies; Pyridines; Retrospective Studies; Risk Factors; Sulfones; Thrombosis; Treatment Outcome	2011
Cardiovascular safety of cyclo-oxygenase-2 inhibitors. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Sulfones	2007